A mouse model of MEPAN demonstrates a role for mitochondrial fatty acid synthesis in iron–sulfur cluster and supercomplex formation

D Deborah G. Murdock (Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia) K Kevin A. Janssen (Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia) K Kierstin Keller (Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia) K Katherine L. Mitchell (Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia) M Maina Beauplan (Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia) W William T. O’Brien (Department of Pediatrics, Division of Human Genetics, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania) L Lia D’Alessandro (Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia) J Jeffrey A. Haltom (Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia) D Douglas C. Wallace

Abstract

MEPAN ( M itochondrial E noyl CoA Reductase P rotein- A ssociated N eurodegeneration) is an early-onset movement disorder characterized by ataxia, dysarthria, and optic atrophy. Here, we report the creation of a mouse model of MEPAN with patient-similar compound heterozygous mutations in the Mecr gene. The MEPAN mouse recapitulates the major hallmarks of MEPAN, including a movement disorder, optic neuropathy, defects in protein lipoylation, and reduced mitochondrial oxidative phosphorylation in the brain. MECR catalyzes the last step in mitochondrial fatty acid synthesis (mtFASII), and the mechanism by which loss of mtFASII leads to neurological disease is unknown. LC–MS/MS-based proteomic analysis of Mecr mutant cerebella identified loss of subunits of complex I of oxidative phosphorylation (OXPHOS) and subunits of the iron–sulfur cluster assembly (ISC) complex. Native gels revealed altered OXPHOS complex and supercomplex formation and changes in binding of the acyl carrier protein (ACP) to mitochondrial complexes. These results demonstrate that MECR plays a key role in the acylation of ACP which is necessary for ACP-LYRM-mediated supercomplex modulation and ISC biogenesis and suggest unique pathways for therapeutics.

Article Details

Volume / Issue Vol. 122, Issue 40
Published October 07, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (9)

D

Deborah G. Murdock

Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia

K

Kevin A. Janssen

Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia

K

Kierstin Keller

Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia

K

Katherine L. Mitchell

Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia

M

Maina Beauplan

Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia

W

William T. O’Brien

Department of Pediatrics, Division of Human Genetics, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania

L

Lia D’Alessandro

Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia

J

Jeffrey A. Haltom

Center for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia

D

Douglas C. Wallace